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pression Rating Scale (HAMD-17) were used to assess treat-
ment outcome (mixed-model repeated-measures regres-
sion analysis).   Results:  Depressed patients receiving their 
preferred treatment (n = 63), whether sertraline or CBT-G, 
responded significantly better than those who did not re-
ceive their preferred therapy (n = 54; p = 0.001). The differ-
ence in outcome between both groups was 8.0 points on the 
HAMD-17 for psychotherapy and 2.9 points on the HAMD-17 
for treatment with antidepressants. Results were not ex-
plained by differences in depression severity or dropout 
rates.   Conclusions:  Patients’ relative preference for medica-
tion versus psychotherapy should be considered when offer-
ing a treatment because receiving the preferred treatment 
conveys an additional and clinically relevant benefit (HAMD-
17: +2.9 points for drugs; +8.0 points for CBT-G) in outcome.
    Copyright © 2010 S. Karger AG, Basel
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  A b s t r a c t
   Background:  Little is known about the influence of de-
pressed patients’ preferences and expectations about treat-
ments upon treatment outcome. We investigated whether 
better clinical outcome in depressed primary care patients is 
associated with receiving their preferred treatment.   Meth-
ods:  Within a randomized placebo-controlled single-centre 
10-week trial with 5 arms (sertraline; placebo; cognitive-be-
havioral group therapy, CBT-G; moderated self-help group 
control; treatment with sertraline or CBT-G according to pa-
tients’ choice), outcomes for 145 primary care patients with 
mild-to-moderate depressive disorders according to DSM-IV 
criteria were investigated. Preference for medication versus 
psychotherapy was assessed at screening using a single 
item. Post-baseline difference scores for the Hamilton De-
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  Introduction
    In routine care, therapy of depression is complicated 
by the fact that providers, especially in primary care, have 
to deal with patients’ disease concepts and treatment 
preferences which can considerably differ from provid-
ers’ own conceptions and preferred treatments   [1–3] . So, 
it is relevant to study how important the fit is between 
patients’ treatment preference and the treatment offered 
for the outcome. Also the option to choose a particular 
therapy instead of being assigned to it by randomization 
might have an effect on the outcome. The findings of the 
few available studies are controversial.
  Thornett   [4]  reviewed studies   [5, 6]   investigating the 
effects of patient preference in trials of treatment of de-
pressive disorders in a general practice setting and con-
cluded that patients who received treatment according to 
their preference did not significantly differ from those 
who were randomized. These results were confirmed by 
a comprehensive meta-analysis of 32 medical and psy-
chological treatment studies   [7] .
    Leykin et al.   [8]  examined treatment outcomes of pa-
tients who got their preferred treatment via randomiza-
tion, and those who did not. To examine this question, 
they used clinical data from a double-blind randomized 
placebo-controlled trial comparing antidepressant medi-
cation to cognitive therapy for outpatients suffering from 
moderate-to-severe depressive disorders   [9] . Most of the 
174 investigated patients with available data stated a pref-
erence for one treatment over the other. Nevertheless, 
there were no significant differences in treatment out-
come between patients who got their treatment of choice 
versus those who did not. Therefore, the authors conclud-
ed that treatment preference was not a key issue in deter-
mining treatment outcome.
    Kocsis et al.   [10]     found patient preference to be a rele-
vant moderator of treatment response for patients suffer-
ing from chronic forms of major depressive disorders: pa-
tients who preferred drugs had higher remission rates 
and lower depression scores at the last study visit when 
receiving medication than when receiving psychotherapy 
and vice versa. Their analysis based on data from 429 pa-
tients who were included in a randomized multicenter 
trial of nefazodone, the Cognitive Behavioral Analysis 
System of Psychotherapy (CBASP) or combination ther-
apy, and who gave information about their treatment 
preference at study entry. However, the validity of this 
study is limited by a low percentage of patients with a 
clear preference for the monotherapies and the absence of 
a placebo group.
    At baseline assessment in a study of enhanced care for 
depression that emphasized improving patient adherence 
to medication   [11] , patients were classified as either recep-
tive or non-receptive to antidepressants based on their re-
sponse to a 4-point Likert scale. Almost half of the patients 
(47.4%) were not receptive to antidepressants and the in-
tervention did not prove cost-effective for them. In con-
trast, for patients indicating receptivity to medication, 
there was a substantial incremental cost-effectiveness ra-
tio. In a recent study, Raue et al.  [12]  addressed the question 
of whether treatment preferences are associated with clin-
ical outcome in primary care patients suffering from major 
depressive disorder. Sixty patients were randomly assigned 
to treatment congruent or incongruent with their treat-
ment preference stated at study entry. Treatments were 20 
weeks of escitalopram or 12 weekly sessions of interper-
sonal psychotherapy. Patients expressed stronger prefer-
ence for interpersonal psychotherapy than for escitalo-
pram and strength of treatment preference was found to be 
more closely associated with the clinical outcome than the 
congruence versus incongruence of treatment preference 
with the assigned therapy. These results are encouraging, 
but clearly preliminary due to the limited sample size.
    According to the study protocol, we analyzed the da  -
  ta from the MinD study   [13]  – a randomized placebo-
controlled single-centre 10-week trial with 5 treatment 
arms – concerning the following pre-specified question:
    Does treatment outcome differ according to whether 
patients receive their preferred treatment (sertraline or 
cognitive-behavioral group therapy, CBT-G)?
    In addition, the following secondary research ques-
tions were addressed:
    (1) How are treatment preferences in terms of pharmaco-
logical or psychological treatment in primary care pa-
tients suffering from mild-to-moderate depressive dis-
orders?
  (2) Do primary care patients with a drug preference differ 
from those with a preference for psychological treat-
ment concerning demographic and clinical variables?
    (3)  Are differences in outcome explained by the way of 
getting the preferred treatment: by randomization or 
by choice?
  (4) Does treatment outcome in the placebo group differ in 
patients who prefer drugs and patients who prefer psy-
chotherapy?
    (5)  Are there any pronounced differences between 
matched patients (receiving their preferred treatment) 
and mismatched patients (who do not receive their 
preferred treatment) in the number of dropouts and 
the mean number of attended visits?  Relevance of Treatment Preferences in 
Response to Depression 
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  Materials  and  Methods
  S t u d y   D e s i g n
    The aim of the study was to investigate the efficacy of an anti-
depressant (sertraline) and CBT-G for treatment of primary care 
patients with mild-to-moderate depressive disorders. The adult 
eligible patients were randomly assigned to 5 arms, 3 of which are 
relevant for this analysis: (1) sertraline (initial daily dose: 50 mg 
with an escalation in dose in steps of 50 mg up to 200 mg per day 
being possible at weeks 2, 4 and 6); (2) short-term CBT-G with 9 
weekly sessions at 90 min each with 5–8 members after an initial 
individual 50-min session [for details see,   14 ]; (3) the patient ran-
domized in this arm could choose (patients’ choice arm; PC) ei-
ther a treatment with sertraline or with CBT-G. Since this article 
deals with effects of treatment preferences on outcome, primarily 
data from the subjects in the active treatment arms were consid-
ered. Results for the patients randomized to placebo were ana-
lyzed in secondary analyses.
    Sertraline and placebo capsules were identical in appearance 
so that blinding was ensured. The duration of the guided self-help 
group (GSG) was as long as the treatment in the other arms (10 
weeks) after an initial individual session with an average duration 
of 50-min nine weekly group sessions (of 1.5 h each) were con-
ducted.     In the GSG, participants had the opportunity to talk 
about their personal situation and their daily life in a supportive 
atmosphere. However, the group leader was not free to conduct 
any psychotherapeutic intervention in the GSG sessions. All CBT-
G and GSG were videotaped.
  Blinding concerning CBT-G versus the psychotherapy control 
condition was not possible. Therefore, the analysis of the effects 
of treatment preferences on outcome in the psychotherapy control 
condition does not make sense, more so as it cannot be deter-
mined whether all patients can be expected not to recognize it as 
a control condition rather than as a preferred treatment. For this 
reason, we did not consider the guided self-help groups in our 
analyses.
    To be enrolled in the study, the patients had to meet the fol-
lowing criteria: a minimum age of 18 years; a diagnosis of sub-
threshold (minor) depression, dysthymia or major depressive dis-
order or depressive disorder not otherwise specified with mild to 
moderate severity and Hamilton Rating Scale for Depression 
(HAMD-17)   [15]  total scores   6  8 and   ^  22. There are also several 
exclusion criteria, explained by Hegerl et al.   [13] . A rather repre-
sentative sample of depressed primary care patients could be in-
cluded, based on referrals by primary care providers and screen-
ing of primary care patients, inclusion of patients with depressive 
disorders not otherwise specified, with minor depression and 
with comorbid anxiety and somatoform disorders as well as the 
entry criterion of a HAMD-17 total score  1  7, but  !  23. Eight points 
in the HAMD-17 was selected as minimum baseline total score in 
our inclusion criteria because lower scores indicate absence of de-
pression   [16] .
    Data were collected between May 2000 and November 2004. 
Our study protocol complied with the revised Declaration of Hel-
sinki  [17]  and Good Clinical Practice guidelines. An independent 
Ethics Review Committee approved the study and all subjects 
gave written informed consent after the procedure and possible 
side effects were fully explained.
  Clinical  Diagnostics
    Patients were diagnosed by trained psychiatrists and clinical 
psychologists according to DSM-IV criteria   [16] . The diagnoses 
based on the German computerized version [DIA-X;   18 ] of the 
fully structured Composite International Diagnostic Interview 
  [19] . This interview was supplemented by a section for the assess-
ment of minor depression according to DSM-IV research criteria.
  P r e f e r e n c e   M e a s u r e s
  Before randomization, participants were asked to complete an 
inventory to measure attitudes toward psychotherapy with the 
original title: ‘Fragebogen zur Messung der Psychotherapiemoti-
vation’ [FMP;   20  ]. The FMP consists of 47 items and 4 subscales.
    To obtain a measure for the preference of psychotherapy ver-
sus drugs, item 36 was chosen to represent the General Treatment 
Preference (FMP-TP): ‘I prefer an efficient drug or a successful 
operation to psychological treatment.’
    Five possible answers are given and only 1 answer has to be 
marked with a cross by the patient: 1 = fully endorsed; 2 = en-
dorsement somewhat restricted; 3 = undetermined; 4 = tendency 
not to agree; 5 = not true at all.
    Subjects with FMP-TP item 36 scores   ^  2 were identified as 
patients with a drug preference, subjects with FMP-TP item 36 
scores   6  4 as patients with a psychotherapy preference, whereas 
patients scoring 3 on this item were considered as having ‘no clear 
treatment preference’.
    Based on the FMP-TP item-score and the received treatment, 
the patients were divided in 2 groups. Matched to treatment of 
choice ‘yes’ (matched: receiving sertraline or CBT-G in accor-
dance with the preference) and matched to treatment of choice 
‘no’ (mismatched: receiving sertraline or CBT -G not in accor-
dance with the preference) – independently of whether they were 
randomly assigned to a certain treatment (sertraline, CBT-G)
or had the chance to choose their treatment (PC: sertraline or 
CBT-G).
  O u t c o m e   M e a s u r e s
    For the present study, the HAMD-17   [15]  was chosen as the 
primary efficacy measure, the standard clinician-administered 
interview for the assessment of depression severity. All HAMD-17 
evaluations were carried out by 2 blinded psychologists. Three 
rater training programs were performed and a 95% rater agree-
ment was achieved.
    Secondary outcomes were response and remission rates. Re-
sponders were defined as patients with a HAMD-17 reduction at 
the individual’s end of treatment of   ^  50% and HAMD-17 end-
points  !  8, remitters as patients with HAMD-17 endpoints  !  8  [13] .
  D a t a   A n a l y s e s
    Explorative statistical analysis was performed with data from 
the intent-to-treat population comprising all randomized patients.
    Analysis of Patient Characteristics
  We conducted     2  tests to test differences in demographic (gen-
der) and clinical characteristics (diagnosis, psychiatric comorbid-
ity, drug and psychotherapy pretreatment in the last 2 years, num-
ber of dropouts) between preference groups for statistical signifi-
cance. Analogously, analyses of variance were applied for metrical 
variables (age, number of attended visits) and Kruskal-Wallis tests 
for ordinal variables (HAMD-17 baseline total scores). Mergl   /Henkel   /Allgaier   /Kramer   /
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  Using a two-sided     2  test, we addressed the question of wheth-
er matched and mismatched patients significantly differed in the 
number of dropouts according to the study protocol.
    Analysis of Outcome Differences
    We applied a mixed-model repeated-measures (MMRM) re-
gression analysis   [21] , using all available data from visits (base-
line, week 2, 4, 6, 8 and 10) to analyze outcome differences. This 
approach allowed us to use all available data, is very flexible in 
time effect modeling and can appropriately handle missing data 
  [22] . Our mixed linear model used the restricted maximum like-
lihood algorithm and the HAMD-17 total scores as the depen-
dent variable. It included random effects for intercept and slope 
as well as fixed class effects for treatment (CBT-G, sertraline), 
treatment preference (FMP-TP   6  4 psychotherapy preference, 
FMP-TP   ^  2 drug preference), visit week and the interaction of 
these factors. Regarding the factor ‘treatment’, the patients who 
could choose their treatment (PC arm) and those who were ran-
domized in the corresponding arms (sertraline, CBT-G) were 
summarized; thus, patients with compatible and incompatible 
treatment expectations could be found in the enlarged CBT-G 
and sertraline groups.
  We used statistical significance of the interaction of treatment 
(sertraline, CBT-G), treatment preference (FMP-TP   6  4 psycho-
therapy preference, FMP-TP   ^  2 drug preference) and visit week 
to indicate whether the rates of change during treatment were dif-
ferent in matched versus mismatched patient groups.
    In an analogous way, differences between matched and mis-
matched patients in therapy outcome were assessed within the 
placebo condition.
    The power of our study to detect a medium (Cohen’s d = 0.50) 
effect size given the sample sizes (mismatch:   !  n = 54; match:
  !  n = 63) and assuming a one-tailed t test for independent sample 
comparison with an      of 0.05 computed with G *  Power  TM , version 
3.0.5   [23]  was 0.85.
    A value of p   ^       0.05 was considered to be statistically signifi-
cant. Statistical analysis was performed by using SPSS software, 
version 12.0   [24]  as well as STATA version 8.0 for mixed model 
analysis   [25] .
  R e s u l t s
    Patients’ Characteristics and Treatment Preferences
  From 1,099 primary care patients screened by primary 
care providers in one German region (Nuremberg), 368 
patients fulfilled the inclusion criteria of the MinD study. 
In total, 145 patients remained for the present analyses: 
51 of 83 patients from the sertraline arm, 39 of 61 patients 
from the CBT-G arm and 55 of 82 patients from the PC 
arm. The distribution of the answer categories for FMP-
TP item 36 in these groups is shown in   table 1  .
    Of the 145 patients, 32 (22.1%) had a stronger prefer-
ence for drugs, and 85 a stronger preference for psycho-
therapy (58.6%). For sample characteristics, see   table 2  .
    Comparison of the 3 categories ‘medication’ (n = 32), 
‘psychotherapy’ (n = 85) and ‘indecisive regarding treat-
ment preference’ (n = 28) revealed significant baseline 
differences in the distribution of main psychiatric diag-
noses. Patients with depressive disorders not otherwise 
specified more often had no clear treatment preferences 
(FMP item 36 = 3; 42.9%) than patients with major de-
p r e s s i v e  d i s o r d e r  ( 3 2 . 1 % )  o r  d o u b l e  d e p r e s s i o n  ( 2 5 % ) .  
Matched and mismatched patients did not significantly 
differ in demographic and clinical variables at baseline 
( table 2 ).
  Outcome  Differences
    The MMRM regression analysis (n = 117) resulted in 
a significant preference   !   treatment   !   time interaction 
(      = –0.89; 95% CI = –1.39 to –0.38; z = –1.39; p = 0.001). 
  Figure 1   reveals that this effect is due to patients in the 
sertraline group having better therapy outcomes if they 
had a stronger preference for drugs than for psychother-
apy, whereas patients in the CBT-G group had a more fa-
  Table  1.  N  umber of patients with or without preferences for either drug treatment or psychotherapy, grouped 
by the therapy received
 T reatment  preference 
 me dication
  (n  =  32) 
 indecisive
  (n  =  28) 
 psychotherapy
  (n  =  85) 
  Sertraline (n = 51)    11 (21.6)    10 (19.6)    30 (58.8) 
  CBT-G (n = 39)  5 (12.8)  7 (17.9)    27 (69.2) 
  Patient preference arm: decision for CBT (n = 20)  5 (25.0)  1 (5.0)    14 (70.0) 
  Patient preference arm: decision for sertraline (n = 35)    11 (31.4)    10 (28.6)    14 (40.0) 
  Fig  ures in parentheses are percentages. 
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vorable therapy response curve if their preference for psy-
chotherapy was greater than their preference for drugs. A 
MMRM subgroup analysis indicates for patients treated 
with sertraline a significant treatment preference  !   time 
interaction (      = 0.62; 95% CI = 0.08–1.15; z = 2.25; p = 
0.025) as well as for patients receiving CBT-G (      = –1.19; 
95% CI = –2.05 to –0.33; z = –2.72; p = 0.007), with the 
latter effect being even more pronounced.
    Considering the HAMD-17 total scores at the end of 
treatment, a moderate effect size of d = 0.42 (95% CI = 
0.004–0.83) in favor of matched patients was found.
    The difference in outcome (HAMD-17; week 10) be-
tween receiving or not receiving the preferred treatment 
as revealed by MMRM was 8.04 points for psychotherapy 
(n = 51; 95% CI = 4.00–12.07 points; p   !   0.001) and 2.86 
points for pharmacotherapy (n = 66; 95% CI = –0.22 to 
5.93 points; p = 0.07). In line with these results, response 
and remission rates in matched patients treated with 
CBT-G (39.0% and 43.9%, respectively) were significant-
ly higher than in mismatched patients receiving CBT-G 
(0%; response rates:     2  = 5.69; d.f. = 1; p = 0.017; remission 
rates:      2  = 6.79; d.f. = 1; p = 0.009), whereas response and 
remission rates in matched versus mismatched patients 
treated with sertraline were comparable. Response and 
remission rates in matched as well as mismatched pa-
tients treated with sertraline or CBT-G are summarized 
in   table 3  .
    Within the placebo group, the differences between 
matched and mismatched patients in the intensity of 
therapeutic changes failed to be statistically significant, 
as reflected by the corresponding match (yes/no)   !   time 
interaction (      = 0.47; 95% CI = –0.14 to 1.09; z = 1.51; p = 
0.13).
    Effects of Randomization and Choice
    Being randomized in a patient preference arm or not 
had no marked influence on outcome difference between 
patients who received their preferred treatment and those 
who did not, as indicated by a match (yes/no)   !   treat-
ment choice (yes/no)   !   time interaction not being sig-
nificant (      = 0.19; 95% CI = –0.61 to 0.99; z = 0.47; p = 
0.64).
  MMRM analysis of the 63 patients receiving their pre-
ferred treatment revealed that having the possibility to 
choose the preferred treatment instead of being assigned 
to it by randomization had no significant additional ef-
fect on treatment outcome (PC   !   time interaction:       = 
0.14; 95% CI = –0.77 to 1.04; z = 0.30; p = 0.77).
  Table  2.  P  atient characteristics
  Treatment preference M  atch to the treatment of choice
medication
(n = 32)
psychotherapy
(n = 85)
indecisive
(n = 28)
p yes
(n   = 63)
no
(n = 54)
p
Age, years (mean   8   SD) 50.0  8  14.8 43.4  8  13.1 44.5  8  15.5 0.08  1  47.4  8  14.3 42.7  8  12.8 0.07  4 
Females 21 (65.6) 56 (65.9) 17 (60.7) 0.88  2  45 (71.4) 32 (59.3) 0.17  2 
HAMD-17 baseline total score, median (IQR) 16 (13–20) 16 (12–20) 17 (14.3–20.8) 0.41  3  16 (13–20) 16 (13–20) 0.84  5 
Diagnoses – – – 0.03*  , 2  – – 0.21  2 
Major depressive disorder 7 (21.9) 28 (32.9) 9 (32.1) – 18 (28.6) 17 (31.5) –
Dysthymic disorder 1 (3.1) 4 (4.7) 0 (0) – 1 (1.6) 4 (7.4) –
Double depression  a  19 (59.4) 34 (40) 7 (25) – 28 (44.4) 25 (46.3) –
Depressive disorder not otherwise specified 3 (9.4) 16 (18.8) 12 (42.9) – 14 (22.2) 5 (9.3) –
Minor depressive disorders  b  2 (6.3) 3 (3.5) 0 (0) – 2 (3.2) 3 (5.6) –
Psychiatric comorbidity  c  8 (25) 21 (24.7) 5 (17.9) 0.74  2  16 (25.4) 13 (24.1) 0.87  2 
Drug pretreatment in the last 2 years 8 (25) 26 (30.6) 8 (28.6) 0.84  2  20 (31.7) 14 (25.9) 0.49  2 
Pretreatment with psychotropic drugs in the last 2 years 8 (25) 22 (25.9) 8 (28.6) 0.95  2  16 (25.4) 14 (25.9) 0.95  2 
Psychotherapeutic pretreatment in the last 2 years 1 (3.1) 8 (9.4) 4 (14.3) 0.31  2  5 (7.9) 4 (7.4) 1  6 
Number of dropouts 12 (37.5) 33 (38.8) 7 (25) 0.41  2  23 (36.5) 22 (40.7) 0.64  2 
Number of attended visits (mean   8   SD) 4.9  8  1.6 5.0  8  1.5 5.5  8  0.9 0.51  3  4.9  8  1.6 5.2  8  1.4 0.24  5 
Fig  ures in parentheses are percentages unless otherwise specified. * p ≤ 0.05.
 1  Univariate ANOVA;   2       2  test;   3  Kruskal-Wallis test;   4  t test for independent samples;   5  Mann-Whitney test;   6  Fisher’s exact test. 
 a  Dysthymic disorder with a current major depressive episode. 
 b  A group of subsyndromal depressive disorders (minor depression according to DSM-IV research criteria; mixed anxiety and depressive disorder; 
mixed anxiety and depressive reaction; persistent mood disorders not otherwise specified). 
 c  According to Composite International Diagnostic Interview [19], diagnoses of anxiety and/or somatoform disorders. 
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  A n a l y s i s   o f   D r o p o u t s
    In addition, it was examined whether the differences 
between matched and mismatched patients in the num-
ber of dropouts and the mean number of attended visits 
were significant. This was not the case (number of drop-
outs: two-sided      2  test:      2  = 0.22; d.f. = 1; p = 0.64; mean 
number of attended visits: two-sided Mann-Whitney test, 
Z = –1.17; p = 0.24).
  Discussion
    The main finding of this study is that treatment pref-
erence is clinically relevant for treatment outcome among 
primary care patients. The effect size computed for the 
differences between matched and mismatched patients in 
final depression scores is moderate (Cohen’ s d = 0.42) 
and resembles that found in other studies   [8] . This is 
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  Fi g .   1.   Improvement differences in mean HAMD-17 total scores (intent-to-treat population; observed case
analysis) between patients with preference for drugs versus psychotherapy for sertraline (  a ) and CBT-G (  b ).
  *   p   ^   0.05, two-sided independent-sample t test. 
  Table  3.  R  esponse and remission rates of depressed primary care patients who had received their preferred treatment (match) or not 
(mismatch), grouped by the therapy received
 Response  rate   R emission  rate 
 match   mismatch   p   match   mismatch   p  
 Sertraline 1  (n = 66)  8/22 (36.4)    18/44 (40.9)    0.72    10/22 (45.5)    19/44 (43.2)    0.86 
 CBT-G 2  (n = 51)    16/41 (39.0)  0/10 (0)   0.02* (FET)   18/41  (43.9)  0 /10  (0)   0.009** (FET) 
  Fig  ures in parentheses are percentages. FET = Fisher’s exact test (which was chosen if expected values were <5; otherwise,      2  tests 
for 2 independent samples were applied). * p ≤ 0.05; ** p ≤ 0.01.
   1   Patients who could choose their treatment and had chosen sertraline as well as those who were randomized in the sertraline arm 
were summarized. 
   2   Patients who could choose their treatment and had chosen CBT-G as well as those who were randomized in the CBT-G arm were 
summarized.  
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noteworthy as very dissimilar treatments have been com-
pared in our study. Similar effects were found in patients 
with chronic forms of major depressive disorder   [10] .
    For patients treated with CBT-G, we found a signifi-
cant and clinically relevant additional benefit of being 
matched to the treatment of choice (8 points in HAMD-
17). In line with this, the response rates were also higher 
in those receiving CBT-G (39.0 vs. 0%).
  These findings are in line with other results indicating 
that in general open-mindedness for psychotherapy at 
baseline is an important predictor for treatment outcome 
in patients treated with psychotherapy   [26] .
  Regarding sertraline, matched patients had better out-
comes than mismatched patients. However, more de-
tailed analysis demonstrated only a statistical trend that 
the outcome of matched patients was superior to that of 
mismatched patients in week 10 (     = 2.86 points; 95% CI: 
–0.22 to 5.93 points). In line with this finding, response 
and remission rates in matched and mismatched patients 
treated with sertraline did not significantly differ. Thus, 
there exists a certain additional benefit of getting the pre-
ferred treatment in the case of depressed primary care 
outpatients receiving sertraline (    HAMD-17: 2.9 points); 
however, this effect is smaller than the corresponding ef-
fect in patients treated with CBT-G.
    Restrictively, it must be taken into account that initial 
preferences can change rapidly depending on initial ex-
periences with the therapeutic intervention   [27] . Since 
the FMP scale was only administered at the beginning of 
the study, we can only speculate about possible changes 
in attitudes over time. However, the unexpected finding 
that 40% of patients with the possibility of therapy choice 
who decided to get sertraline initially did not tend to pre-
fer pharmacotherapy in the FMP-TP item might indicate 
changes in initial reservations concerning antidepres-
sants, due to later extensive education about sertraline 
and its desired effects. Thus, the differences between 
matched and mismatched patients in response to sertra-
line might have been more pronounced if treatment pref-
erences had been assessed after this information had been 
given.
    The secondary research questions will be discussed 
below.
    The analysis of the treatment preferences of 145 pri-
mary care patients suffering from mild-to-moderate de-
pressive disorders revealed that most (58.6%) favor a psy-
chological treatment over a drug treatment, and 19.3% 
were undetermined.
    Indecisiveness and a negative treatment expectation 
could be symptoms of the depressive syndrome. The 
somewhat lower preference for drugs probably reflects 
the widespread prejudices about antidepressants [e.g.  28  ], 
especially in the general population [e.g.   2 ]. Surveys in 2 
German cities revealed that about 80% of the population 
believe that antidepressants are addictive and about two-
thirds that they change one’s personality   [2] .
    In the present study, depressed primary care outpa-
tients with a stronger preference for drugs did not sig-
nificantly differ from those with a stronger preference for 
psychotherapy in demographic and clinical variables. 
Thus, it is unlikely that preference of drugs versus psy-
chotherapy constitutes distinct clinical subgroups of pa-
tients suffering from depressive disorders.
  The study design allowed us to address the question of 
whether patients getting their preferred treatment by 
choice (PC arm) have significant benefit in terms of treat-
ment outcome, as compared to patients who receive their 
preferred treatment by chance, after randomization. This 
possibility can clearly be rejected. Thus, the benefits re-
sulting from the act of choosing seem to be too small to 
result in considerable gains in terms of therapy outcome 
(as hypothesized by Leykin et al.  [8] ). More crucial seems 
to be fitting of the initial therapy preference and the re-
ceived therapy.
    The pronounced association between treatment pref-
erence and outcome as identified in the active treatment 
arms was less clear in the placebo arm. Insufficient sta-
tistical power might be the explanation for the lack of 
significant association between treatment preference and 
the intensity of therapeutic improvement in this group.
    Receiving non-preferred therapy did not increase the 
probability of dropping out in our study since matched 
and mismatched patients did not significantly differ in 
the number of dropouts and the number of attended vis-
its. So, the compliance to the received therapy does not 
seem to be influenced by the match or mismatch with 
initial treatment preference. Similar results were ob-
tained by Leykin et al.   [8] .
  L i m i t a t i o n s
    A general limitation of this study is the fact that only 
subjects who agreed to be randomized were included and 
that only patients who were randomized in the PC arm 
had the option to choose. Therefore, patients with prefer-
ences for a certain treatment strong enough to prompt 
them to refuse participation could not be investigated.
    Another issue is related to the fact that CBT-G was of-
fered as group psychotherapy in the context of the MinD 
study. In view of the fact that patients differ substantially 
in their attitudes toward individual compared to group  Mergl   /Henkel   /Allgaier   /Kramer   /
Hautzinger    /Kohnen   /Coyne   /Hegerl 
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psychotherapy, participants might have responded posi-
tively to the FMP-TP item in our study in general, yet had 
different attitudes toward group psychotherapy. This 
probably was the case as 40% of the patients in the prefer-
ence arm who decided to receive sertraline had an initial 
preference for psychological treatment in general (but 
possibly not for group CBT-G resulting in a decision in 
favor of sertraline). However, this assumption is clearly 
speculative and can only be confirmed in studies using 
an item specifically addressing preference for group psy-
chotherapy.
    Further, we did not measure participants’ pretreat-
ment concerns about continuing antidepressant treat-
ment in the presence of side effects. This can signal chal-
lenges to the completion of an acute phase treatment, as 
a recent study of Warden et al.  [29]  has shown. The use of 
the HAMD-17 as a measure of outcome might be anoth-
er limitation   [30] . Although the HAMD-17 is the most 
commonly used rating scale for depression severity   [30] , 
the ability of the HAMD-17 in judging depression sever-
ity is still doubtful   [31] .
    The median HAMD-17 score of the patients enrolled 
was markedly below most clinical trials in major depres-
sive disorder. Therefore, significant differences between 
active treatment and placebo treatment are difficult to 
find. However, minor depression is common in primary 
care and is associated with high levels of functional im-
pairment   [32] . Furthermore, there are convincing argu-
ments that the benefit of antidepressants in mild depres-
sion is considerably larger than that suggested by placebo/
active treatment differences in clinical trials  [33] . Thus, it 
is important to consider this large group of high utilizers 
of primary care services   [34] .
  Conclusion
    The treatment preference of a depressed patient for 
psychotherapy or pharmacotherapy is a relevant factor 
influencing treatment outcome. The outcome difference 
between receiving pharmaco- or psychotherapy in line 
with or contrary to the individual treatment preference is 
clearly of clinical significance.
    Therefore, treatment preferences have to be incorpo-
rated as an important element in clinical decisions about 
treatment strategies. In this context, integration of pa-
tients’ treatment preferences in shared decision making 
interventions in primary care of depression  [35]  is of spe-
cial interest. Future studies should account for mediating 
factors like treatment satisfaction and provide the possi-
bility to assess possible changes of treatment preferences 
in the course of therapy.
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